AstraZeneca PLC
21 February 2002
DEALING BY DIRECTORS
COMPANIES ACT 1985 SECTION 324/329
WE HEREBY INFORM YOU THAT, ON 19 FEBRUARY 2002, WE WERE NOTIFIED BY MR A B T
STAVLING, A DIRECTOR OF THE COMPANY, THAT, ON 15 FEBRUARY 2002, HE SOLD OPTIONS
OVER ASTRAZENECA PLC ORDINARY SHARES OF USD0.25 EACH AS FOLLOWS:-
NUMBER OF OPTIONS SOLD SALE PRICE PER OPTION DATE OF SALE
2,717 318.18SEK 15.02.02
3,267 306.14SEK 15.02.02
THESE OPTIONS WERE ORIGINALLY GRANTED TO MR STAVLING OVER SHARES IN ASTRA AB
UNDER THE ASTRA SHAREHOLDER VALUE INCENTIVE PLAN AND WERE CONVERTED INTO OPTIONS
OVER ORDINARY SHARES IN ASTRAZENECA PLC IN APRIL 1999. DETAILS OF THE
UNDERLYING ASTRAZENECA SHARES OVER WHICH THE OPTIONS WERE HELD ARE AS FOLLOWS:-
NUMBER OF ASTRAZENECA EFFECTIVE OPTION CLOSING PRICE OF ASTRAZENECA
SHARES OVER WHICH PRICE PER SHARE SHARES ON DATE OPTIONS
OPTIONS WERE HELD WERE SOLD
3,655 298.28SEK 533SEK
4,395 316.13SEK 533SEK
FOLLOWING THESE TRANSACTIONS, MR STAVLING HOLDS OPTIONS OVER 92,340 ORDINARY
SHARES OF ASTRAZENECA PLC.
G H R MUSKER
COMPANY SECRETARY
21 FEBRUARY 2002
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.